Search Results - "HILL, SALLY A."

Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice by Gil-Bernabé, Ana M., Ferjančič, Špela, Tlalka, Monika, Zhao, Lei, Allen, Philip D., Im, Jae Hong, Watson, Karla, Hill, Sally A., Amirkhosravi, Ali, Francis, John L., Pollard, Jeffrey W., Ruf, Wolfram, Muschel, Ruth J.

“…Tissue factor (TF) expression by tumor cells correlates with metastasis clinically and supports metastasis in experimental settings. However, the precise…”
Get full text

Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation by Kersemans, Veerle, Cornelissen, Bart, Hueting, Rebekka, Tredwell, Matthew, Hussien, Kamila, Allen, Philip D, Falzone, Nadia, Hill, Sally A, Dilworth, Jonathan R, Gouverneur, Veronique, Muschel, Ruth J, Smart, Sean C

“…Preclinical imaging requires anaesthesia to reduce motion-related artefacts. For direct translational relevance, anaesthesia must not significantly alter…”
Get full text

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors by TOZER, Gillian M, AKERMAN, Simon, PETTYJOHN, Katie L, PRISE, Vivien E, REYES-ALDASORO, Constantino C, RUHRBERG, Christiana, SHIMA, David T, KANTHOU, Chryso, CROSS, Neil A, BARBER, Paul R, BJÖRNDAHL, Meit A, GRECO, Olga, HARRIS, Sheila, HILL, Sally A, HONESS, Davina J, IRESON, Christopher R

“…Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to…”
Get full text

The development of combretastatin A4 phosphate as a vascular targeting agent by Chaplin, David J, Hill, Sally A

“…This overview summarizes the preclinical development of tubulin-depolymerizing agents as vascular targeting agents, leading to the identification of…”
Get more information

Nitric Oxide Synthase Inhibition Enhances the Tumor Vascular-Damaging Effects of Combretastatin A-4 3-O-Phosphate at Clinically Relevant Doses by Tozer, Gillian M, Prise, Vivien E, Lewis, Gemma, Xie, Shaoping, Wilson, Ian, Hill, Sally A

“…Purpose: The therapeutic potential of combining the prototype tumor vascular-disrupting agent combretastatin A-4 3- O -phosphate (CA-4-P) with systemic nitric…”
Get full text

VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice by Ferjančič, Špela, Gil-Bernabé, Ana M., Hill, Sally A., Allen, Philip D., Richardson, Peter, Sparey, Tim, Savory, Edward, McGuffog, Jane, Muschel, Ruth J.

“…Pulmonary metastasis is a frequent cause of poor outcome in cancer patients. The formation of pulmonary metastasis is greatly facilitated by recruitment of…”
Get full text

Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect by Kleibeuker, Esther A, Fokas, Emmanouil, Allen, Philip D, Kersemans, Veerle, Griffioen, Arjan W, Beech, John, Im, Jaehong H, Smart, Sean C, Castricum, Kitty C, van den Berg, Jaap, Schulkens, Iris A, Hill, Sally A, Harris, Adrian L, Slotman, Ben J, Verheul, Henk M, Muschel, Ruth J, Thijssen, Victor L

“…The extent of tumor oxygenation is an important factor contributing to the efficacy of radiation therapy (RTx). Interestingly, several preclinical studies have…”
Get full text

Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy by Tozer, Gillian M., Ameer-Beg, Simon M., Baker, Jennifer, Barber, Paul R., Hill, Sally A., Hodgkiss, Richard J., Locke, Rosalind, Prise, Vivien E., Wilson, Ian, Vojnovic, Borivoj

“…The blood supply of solid tumours affects the outcome of treatment via its influence on the microenvironment of tumour cells and drug delivery. In addition,…”
Get full text

Vascular effects dominate solid tumor response to treatment with combretastatin A‐4‐phosphate by Jane Lunt, Sarah, Akerman, Simon, Hill, Sally A., Fisher, Matthew, Wright, Victoria J., Reyes‐Aldasoro, Constantino C., Tozer, Gillian M., Kanthou, Chryso

“…Vascular‐targeted therapeutics are increasingly used in the clinic. However, less is known about the direct response of tumor cells to these agents. We have…”
Get full text

The biology of the combretastatins as tumour vascular targeting agents by TOZER, GILLIAN M., KANTHOU, CHRYSO, PARKINS, CHARLES S., HILL, SALLY A.

“…Summary The tumour vasculature is an attractive target for therapy. Combretastatin A‐4 (CA‐4) and A‐1 (CA‐1) are tubulin binding agents, structurally related…”
Get full text

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature by DAVIS, Peter D, DOUGHERTY, Graeme J, HILL, Sally A, BLAKEY, David C, GALBRAITH, Susan M, TOZER, Gillian M, HOLDER, Angela L, NAYLOR, Matthew A, NOLAN, John, STRATFORD, Michael R. L, CHAPLIN, David J

“…Physiological differences between tumor and normal vasculature provide a target for drug discovery. In particular, the immature nature of tumor vasculature may…”
Get full text

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature by DARK, G. G, HILL, S. A, PRISE, V. E, TOZER, G. M, PETTIT, G. R, CHAPLIN, D. J

“…Selective induction of vascular damage within tumors represents an emerging approach to cancer treatment. Histological studies have shown that several…”
Get full text

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate by PEDLEY, R. Barbara, HILL, Sally A, BOXER, Geoffrey M, FLYNN, Aiden A, BODEN, Robert, WATSON, Rebecca, DEARLING, Jason, CHAPLIN, David J, BEGENT, Richard H. J

“…Solid tumors have a heterogeneous pathophysiology, which has a major impact on therapy. Using SW1222 colorectal xenografts grown in nude mice, we have shown…”
Get full text

The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability by BEAUREGARD, Daniel A, HILL, Sally A, CHAPLIN, Dai J, BRINDLE, Kevin M

“…The acute effects of the antivascular drug, combretastatin A4 phosphate, on tumor energy status and perfusion were assessed using magnetic resonance imaging…”
Get full text

Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503 by Hill, Sally A, Toze, Gillian M, Pettit, George R, Chaplin, David J

“…Tubulin depolymerizing drugs, which selectively disrupt tumour neovasculature, have recently been identified. The lead drug in this class, combretastatin A4…”
Get more information

Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS by Beauregard, Daniel A., Pedley, R. Barbara, Hill, Sally A., Brindle, Kevin M.

“…The effects of two anti‐vascular agents, combretastatin A4 phosphate (CA4P), and 5,6‐dimethylxanthenone‐4‐acetic acid (DMXAA), on the perfusion of two human…”
Get full text

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models by Hill, Sally A., Chaplin, David J., Lewis, Gemma, Tozer, Gillian M.

“…Tubulin depolymerizing drugs that selectively disrupt tumour‐associated vasculature have recently been identified. The lead drug in this class, combretastatin…”
Get full text

Synergy between vascular targeting agents and antibody-directed therapy by Pedley, R Barbara, El-Emir, Ethaar, Flynn, Aiden A, Boxer, Geoffrey M, Dearling, Jason, Raleigh, James A, Hill, Sally A, Stuart, Sam, Motha, Reeya, Begent, Richard H J

“…Tumor heterogeneity necessitates the use of combined therapies. We have shown that combining antibody-directed therapy with antivascular agents converts a…”
Get more information

Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations by Powell, Melanie E.B, Collingridge, David R, Saunders, Michele I, Hoskin, Peter J, Hill, Sally A, Chaplin, David J

“…Background and purpose: Carbogen (95%O 2, 5%CO 2) is being used in clinical trials as a hypoxic radiosensitiser. Tolerance to carbogen can be a problem, this…”
Get full text

Enhancement of vascular targeting by inhibitors of nitric oxide synthase by Davis, Peter D, Tozer, Gillian M, Naylor, Matthew A, Thomson, Peter, Lewis, Gemma, Hill, Sally A

“…This study investigates the enhancement of the vascular targeting activity of the tubulin-binding agent combretastatin A4 phosphate (CA4P) by various…”
Get more information